Objective
Emerging evidence suggests that methionine oxidation can directly affect protein function and may be linked to cardiovascular disease. The objective of this study was to define the role of the methionine sulfoxide reductase A (MsrA) in models of vascular disease and identify its signaling pathways.
Approach and Results
MsrA was readily identified in all layers of the vascular wall in human and murine arteries. Deletion of the MsrA gene did not affect atherosclerotic lesion area in apolipoprotein E-deficient mice, and had no significant effect on susceptibility to experimental thrombosis after photochemical injury. In contrast, the neointimal area after vascular injury due to complete ligation of the common carotid artery was significantly greater in MsrA-deficient compared to control mice. In aortic vascular smooth muscle cells (VSMC) lacking MsrA, cell proliferation was significantly increased due to accelerated G1/S transition. In parallel, cyclin D1 protein and cdk4/cyclin D1 complex formation and activity were increased in MsrA-deficient VSMC, leading to enhanced Rb phosphorylation and transcription of E2F. Finally, MsrA-deficient VSMC exhibited greater activation of ERK1/2 that was caused by increased activity of the Ras/Raf/MEK signaling pathway.
Conclusion
Our findings implicate MsrA as a negative regulator of VSMC proliferation and neointimal hyperplasia after vascular injury through control of the Ras/Raf/MEK/ERK1/2 signaling pathway.